Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study
|ClinicalTrials.gov Identifier: NCT01783301|
Recruitment Status : Completed
First Posted : February 4, 2013
Last Update Posted : February 4, 2013
The overall objectives of this trial are to:
- To explore the efficacy and safety of using either antral follicle count (AFC) or anti-Mullerian hormone (AMH) to guide the starting dose of GONAL-f® in ovarian stimulation for Assisted Reproductive Technology (ART).
- To assess the differences in both ovarian response and clinical pregnancy rate between subjects with different AFC and AMH levels undergoing ART.
|Condition or disease||Intervention/treatment||Phase|
|Infertility||Drug: FSH||Phase 4|
This trial is a prospective, Phase IV 2 arm trial exploring the efficacy and safety of using either AFC or AMH to guide the starting GONAL-f® dose for the stimulation treatment of subjects undergoing ART.
Throughout the trial period and before the start of a routine ART cycle, investigators will propose the trial to their potential subjects. All subjects who agree to participate in the trial must sign a consent form, irrespective of whether or not they ultimately agree to have their dose determined by the study protocol. Eligible subjects will be randomised in blocks of 4 at each site via a computer generated random number list to either the AFC guided arm (control) or the AMH guided arm (treatment). The starting doses of GONAL-f® for each arm will be based on the study algorithms, using AFC or AMH guidance.
The investigator will then enter initiate ovarian stimulation with an individualised GONAL-f® dose for that specific subject. This will be maintained for the first 5 days of stimulation after which the dose can be modified based on investigator decision and in accordance with the site's routine clinical practice.
Female partners of infertile couples requiring Assisted Reproductive Technology (ART) treatment.
Data Analysis and Statistics
The primary end-point proportion of patients with desired number of retrieved oocytes (8-12) will be compared between the 2 arms using the chi -square test. The null hypothesis will be that there is no difference between the 2 arms in primary end-point, with the p level set at p=0.05. The secondary end-points will also be compared between the 2 arms using either the Student's t test or anova test.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||348 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase IV, Open-label 2 Arm Trial to Compare the Efficacy and Safety of a Pre-defined Dose of GONAL-f® Based on Antral Follicle Count [Follicles ≥2mm - <11mm]), or AMH for Ovarian Stimulation in Subjects Undergoing Assisted Reproductive Technology (ART) Treatment.|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||August 2012|
|Actual Study Completion Date :||December 2012|
Active Comparator: Antral follicle count
Start dose of recombinant Follicle-Stimulating Hormone (rFSH) based on AFC guide
Other Name: GONAL-f
Active Comparator: Anti-Mullerian Hormone
Start dose of FSH based on AMH guide
Other Name: GONAL-f
- Number of oocytes retrieved [ Time Frame: 30 minutes after oocyte retrieval completed ]
- Symptoms of ovarian hyperstimulation syndrome (OHSS) [ Time Frame: in 10 days after hCG injection ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01783301
|Research Center for Genetics and Reproductive Health|
|Ho Chi Minh, Vietnam|
|Principal Investigator:||Tuong M Ho, MD||Vietnam National University HCMC|